Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 2372 |
| INN | Bococizumab |
| Status | Terminated |
| Drug code(s) | PF-04950615, RN316 |
| Brand name | None |
| mAb sequence source | mAb humanized |
| General Molecular Category | Naked monospecific |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG2 |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | PCSK9 |
| Indications of clinical studies | High cholesterol |
| Primary therapeutic area | Cardiovascular / hemostasis disorders |
| Most advanced stage of development (global) | Terminated at Phase 3 |
| Status | Inactive |
| Start of clinical phase (IND filing or first Phase 1) | October 15, 2009 |
| Start of Phase 2 | June 15, 2011 |
| Start of Phase 3 | October 15, 2013 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Pfizer |
| Licensee/Partner | None |
| Comments about company or candidate | Terminated due to changes in treatment and market landscape. Total of 5 Phase 3 studies recruiting as of Feb 2014. NCT01968980, NCT01968954 Phase 3 studies recruiting as of Oct 2013. NCT01968967 Phase 3 recruiting as of Dec 2013 |
| Full address of company | 66 Hudson Boulevard East, New York, NY 10001-2192 USA North America United States of America https://www.pfizer.com/contact |
None
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |